U.S. markets closed
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • Dow 30

    34,196.82
    +322.58 (+0.95%)
     
  • Nasdaq

    14,369.71
    +97.98 (+0.69%)
     
  • Russell 2000

    2,332.92
    +29.45 (+1.28%)
     
  • Crude Oil

    73.26
    +0.18 (+0.25%)
     
  • Gold

    1,774.40
    -9.00 (-0.50%)
     
  • Silver

    26.01
    -0.10 (-0.39%)
     
  • EUR/USD

    1.1937
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • GBP/USD

    1.3932
    -0.0031 (-0.22%)
     
  • USD/JPY

    110.8700
    -0.0920 (-0.08%)
     
  • BTC-USD

    34,916.66
    +1,753.69 (+5.29%)
     
  • CMC Crypto 200

    840.40
    +53.78 (+6.84%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Recap: Viela Bio Q4 Earnings

·1 min read

Shares of Viela Bio (NASDAQ:VIE) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 36.17% year over year to ($0.60), which beat the estimate of ($0.70).

Revenue of $9,336,000 declined by 68.88% from the same period last year, which beat the estimate of $5,550,000.

Outlook

Viela Bio hasn't issued any earnings guidance for the time being.

View more earnings on VIE

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $70.66

Company's 52-week low was at $25.02

Price action over last quarter: Up 50.07%

Company Overview

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.